136 related articles for article (PubMed ID: 20855947)
1. RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling.
Berberich SJ
Cell Cycle; 2010 Sep; 9(18):3640-1. PubMed ID: 20855947
[No Abstract] [Full Text] [Related]
2. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
3. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
Phillips A; Teunisse A; Lam S; Lodder K; Darley M; Emaduddin M; Wolf A; Richter J; de Lange J; Verlaan-de Vries M; Lenos K; Böhnke A; Bartel F; Blaydes JP; Jochemsen AG
J Biol Chem; 2010 Sep; 285(38):29111-27. PubMed ID: 20659896
[TBL] [Abstract][Full Text] [Related]
4. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Datta S; Bucks ME; Koley D; Lim PX; Savinov SN
Bioorg Med Chem; 2010 Aug; 18(16):6099-108. PubMed ID: 20638853
[TBL] [Abstract][Full Text] [Related]
5. N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
Hayashi R; Wang D; Hara T; Iera JA; Durell SR; Appella DH
Bioorg Med Chem; 2009 Dec; 17(23):7884-93. PubMed ID: 19880322
[TBL] [Abstract][Full Text] [Related]
6. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
7. Understanding the interaction of 14-3-3 proteins with hDMX and hDM2: a structural and biophysical study.
Srdanović S; Wolter M; Trinh CH; Ottmann C; Warriner SL; Wilson AJ
FEBS J; 2022 Sep; 289(17):5341-5358. PubMed ID: 35286747
[TBL] [Abstract][Full Text] [Related]
8. HdmX overexpression inhibits oncogene induced cellular senescence.
Miller KR; Kelley K; Tuttle R; Berberich SJ
Cell Cycle; 2010 Aug; 9(16):3376-82. PubMed ID: 20724842
[TBL] [Abstract][Full Text] [Related]
9. c-Abl phosphorylates Hdmx and regulates its interaction with p53.
Zuckerman V; Lenos K; Popowicz GM; Silberman I; Grossman T; Marine JC; Holak TA; Jochemsen AG; Haupt Y
J Biol Chem; 2009 Feb; 284(6):4031-9. PubMed ID: 19075013
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.
Pereg Y; Shkedy D; de Graaf P; Meulmeester E; Edelson-Averbukh M; Salek M; Biton S; Teunisse AF; Lehmann WD; Jochemsen AG; Shiloh Y
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5056-61. PubMed ID: 15788536
[TBL] [Abstract][Full Text] [Related]
12. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Structural Determinant for Selective Targeting of HDMX.
Ben-Nun Y; Seo HS; Harvey EP; Hauseman ZJ; Wales TE; Newman CE; Cathcart AM; Engen JR; Dhe-Paganon S; Walensky LD
Structure; 2020 Jul; 28(7):847-857.e5. PubMed ID: 32359398
[TBL] [Abstract][Full Text] [Related]
14. HDM2 and HDMX Proteins in Human Cancer.
Hároníková L; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
[TBL] [Abstract][Full Text] [Related]
15. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
[TBL] [Abstract][Full Text] [Related]
16. A stapled p53 helix overcomes HDMX-mediated suppression of p53.
Bernal F; Wade M; Godes M; Davis TN; Whitehead DG; Kung AL; Wahl GM; Walensky LD
Cancer Cell; 2010 Nov; 18(5):411-22. PubMed ID: 21075307
[TBL] [Abstract][Full Text] [Related]
17. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
18. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.
Medina-Medina I; García-Beltrán P; de la Mora-de la Mora I; Oria-Hernández J; Millot G; Fahraeus R; Reyes-Vivas H; Sampedro JG; Olivares-Illana V
Mol Cell Biol; 2016 Aug; 36(16):2195-205. PubMed ID: 27215386
[TBL] [Abstract][Full Text] [Related]
20. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
